Medica Scientia Innovation Research clinical trials
Medica Scientia Innovation Research is the lead sponsor of 3 current clinical trials in our EU (CTIS) register. The drugs named most often in its trials are Camizestrant, Fulvestrant and Goserelin.
Medica Scientia Innovation Research in the EU trials register (CTIS)
3 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System with Medica Scientia Innovation Research as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Countries |
|---|---|---|---|
|
An international, multicenter, adaptive platform study with independent diagnostic and therapeutic modules to evaluate diagnostic and theranostic agents in solid tumors with active brain metastases (the THERANOVA study; NMN-02)
2025-523824-39-01 · CTIS ↗ · Neoplasms
|
Phase 2 | Authorised | Germany |
|
A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)
2026-525328-10-00 · Neoplasms
|
Phase 2 | Ongoing | Spain, Italy, Germany |
|
PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT PLUS RIBOCICLIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+) BREAST CANCER (THE CADILLAC STUDY)
2024-520027-88-00 · CTIS ↗ · Neoplasms
Drugs: Camizestrant, Ribociclib |
Phase 2 | Ongoing | Spain, Germany, Italy |
Drugs in Medica Scientia Innovation Research trials
5 compoundsDrugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
By trial register
| Register | Trials | Recruiting |
|---|---|---|
| EU register (CTIS) | 3 | — |
A trial with sites in more than one country appears in each of those registers.
Questions about Medica Scientia Innovation Research trials
How many clinical trials does Medica Scientia Innovation Research sponsor?
Medica Scientia Innovation Research is the lead sponsor of 3 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Which drugs is Medica Scientia Innovation Research testing?
Its current trials name 5 drugs and biologicals as interventions. The most frequent are Camizestrant (1), Fulvestrant (1), Goserelin (1), Ribociclib (1) and Zongertinib (1). The number in brackets is how many of its trials name each drug.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.